B. Solomon

发表

An inverse stage‐shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID‐19 pandemic

Maarten J. IJzerman, J. Emery, P. Gibbs, 2021, Asia-Pacific journal of clinical oncology.

An inverse stage-shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID-19 pandemic

Maarten J. IJzerman, J. Emery, P. Gibbs, 2020, medRxiv.

Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results

Matthew J. Davis, R. Yelensky, D. Carbone, 2022, Nature Medicine.

Impact of COVID-19 on cancer service delivery: a follow-up international survey of oncology clinicians

N. Pavlakis, M. IJzerman, L. Mileshkin, 2021, ESMO Open.

Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

T. Mok, G. Veronesi, D. Planchard, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Managing haematology and oncology patients during the COVID‐19 pandemic: interim consensus guidance

E. Wood, A. Cheng, J. Szer, 2020, The Medical journal of Australia.

Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress.

E. Felip, B. Levy, S. Rosner, 2023, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS G12C mutation: a randomised, open-label, phase 3 trial

C. Dooms, Melissa L. Johnson, S. Novello, 2023, The Lancet.

Early ctDNA dynamics and efficacy of lorlatinib in patients with treatment-naïve, advanced, ALK-positive non-small cell lung cancer.

A. Shaw, C. Chiu, P. Tomasini, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.

Jeffrey W. Clark, A. Iafrate, S. Fox, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rociletinib in EGFR-mutated non-small-cell lung cancer.

J. Neal, H. Wakelee, L. Sequist, 2015, The New England journal of medicine.

First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M).

H. Wakelee, L. Sequist, B. Solomon, 2014 .

A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study

P. Gibbs, J. Desai, S. Dawson, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Intracranial and systemic efficacy of repotrectinib in advanced ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1.

C. Dooms, A. Drilon, E. Felip, 2023, Journal of Clinical Oncology.

Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement.

Jeffrey W. Clark, A. Iafrate, S. Ou, 2012 .

First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014)

F. Cappuzzo, T. Mok, Yi-long Wu, 2014 .

Supplementary Material to the manuscript: An inverse stage-shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID-19 pandemic

Maarten J. IJzerman, J. Emery, P. Gibbs, 2020 .

M. Alexander, I. Ruderman, B. Solomon, 2023, Lung cancer.

KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC).

C. Dooms, E. Felip, M. Schuler, 2023, Journal of Clinical Oncology.

Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer.

G. Scagliotti, J. Engelman, A. Shaw, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

A protocol for a systematic review with prospective individual patient data meta-analysis in EGFR mutant NSCLC with brain metastases to assess the effect of SRS + Osimertinib compared to Osimertinib alone: the STARLET collaboration.

A. Nichol, A. Sahgal, R. Soo, 2023, medRxiv.

Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer

G. Scagliotti, J. Engelman, A. Shaw, 2012 .